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Ceftriaxone has potent activity against a broad range of Gram-positive and Gram-
negative bacteria. While it is Hjminat^ mainly by the kidney, 10-20% of the drug is
eliminated in the bile and ceftriaxone salt precipitates have been described in the
gallbladder of animals dosed with ceftriaxone. The purpose of the present study was
to investigate the incidence of binary litniasis 6 and 12 months after treatment with
ceftriaxone and to compare it with that in patients treated with amoxyciUin/
clavulanate. Biliary ultrasonography was performed at the start of treatment, at
6 months and at 12 months after the beginning of the study. One hundred patients
were randomized and 74 were evaluable: 34 were given amoxycillin/clavulanate,
40 ceftriaxone. Gallbladder litniasis developed in one patient 12 months after the
amoxycillin/clavulanate treatment and in none in the ceftriaxone treatment arm.
Biliary precipitate during ceftriaxone treatment was not looked for because this
phenomenon was not known at the beginning of the study, but gallbladder precipita-
tion that was seen in two patients given ceftriaxone during and at the end of
treatment, respectively, resolved spontaneously.
In conclusion, ceftriaxone treatment does not appear to lead to gallstone forma-
tion more often than an antibiotic that is not eliminated through the bile.
Introduction
Ceftriaxone has demonstrated potent activity against a broad range of Gram-positive
and Gram-negative bacteria (Cleeland & Squires, 1984). Its long half life allows once-a-
day administration (Patel & Kaplan, 1984; Baumgartner & Glauser, 1983). This
property has permitted the use of ceftriaxone in a variety of bacterial infections
including pneumonia, biliary and urinary tract infections, endocarditis, meningitis and
gonococcal infections.
While ceftriaxone is mainly eliminated in the urine, 10-20% of the drug is eliminated
in the bile (Hayton, Schandlik & Stoeckel, 1986; Hayton & Stoeckel, 1986; Brogard et
al., 1987). Observations in dogs and monkeys (Teelmann, Scharer & Udaka, 1982) have
occasionally shown precipitation of the calcium salt of ceftriaxone in the gallbladder
after prolonged intravenous administration. In humans, precipitation during or after
ceftriaxone administration has been described. In a young patient population, gall-
bladder ultrasonography demonstrated that the precipitation disappeared after comple-
tion of treatment (Schaad, 1986; Schaad & Tschappeler, 1987). Nevertheless, concerns
have been raised that this accumulation may lead to gallstone formation.
689
0305-7453/90/O4O689 + 07 $0100/0 © 1990 The British Society for Antimicrobial Chemotherapy
690 A. Comettaetal
The purpose of the present study was to investigate the incidence of biliary lithiasis 6
and 12 months after treatment with ceftriaxone and to compare it with that in patients
treated with amoxycillin/clavulanate. This latter antibiotic combination was chosen
because it has indications similar to those for ceftriaxone, while its biliary concentra-
tion is negligible and biliary lithiasis has not been reported to develop in association
with its use.
Method
Patients
Patients who presented a documented bacterial infection which required antibacterial
therapy foi more than seven days were eligible for the study. Patients were excluded if
they had had a cholecystectomy, known biliary lithiasis, an allergy to /Mactam
antibiotic-, renal insufficiency with a creatinine clearance < lOml/min, an infection
with an organism that was resistant to ceftriaxone or amoxycillin/clavulanate, or were
pregnant.
Oral informed consent was obtained from the patient. The trial was approved by the
Ethics Committee of the hospital.
Experimental design
This was a prospective open randomized study. Patients received either ceftriaxone 2 g
once-a-day or amoxycillin/clavulanate 1-2 g 4-6 times a day.
Clinical and routine laboratory data
Upon entry into the study, the patient's history was obtained and a physical examina-
tion performed which was repeated during the trial and at the end of the treatment.
Before beginning therapy, blood for culture (two sets) was taken, as well as samples
from the site of infection. In addition, haemoglobin, haematocrit, leucocyte count,
differential blood count, creatinine, blood urea nitrogen, total bilirubin, ASAT, ALAT,
alkaline phosphatase, cholesterol and triglycerides were measured in all patients at
study entry, as well as on days 3, 7, and at the end of treatment.
Biliary ultrasonography was performed at the time of randomization and at 6 and
12 months after the entry into the study, with a Phillips Sono DiagnostB,
Diasonics ds-J or Hitachi EUB-25 with transducers of 3-5 and 5 MHz. The physician
(AA) who performed the ultrasonography did not know which antibiotic the patient
had received.
The gallbladder was scanned through its long axis from a lower intercostal and/or
preferably subcostal approach. The plane of section was swept medially and laterally to
allow visualization of the entire volume of the gallbladder. Gallbladder lithiasis was
considered to be present when an intraluminal echo with an acoustic shadow was
detected. In some cases, many small calculi did not show an acoustic shadow but their
presence could be confirmed when the intraluminal echoes moved with changes in
patient position. Gallbladder sludge and precipitation were defined as intraluminal
echoes forming a fluid-fluid level that moved very slowly with change in patient
position, without producing a postacoustic shadowing (Cooperberg & Gibney, 1987).
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Statistical analysis
Differences between the two groups were tested for significance by Student's test (age
and treatment duration), Fisher's test (sex, infections by site and organisms, gallbladder
lithiasis) and Chi-square test (Dunnet & Gent, 1977).
Results
One hundred patients were randomized in this study; 49 received ceftriaxone and 51
amoxycillin/clavulanate. Twenty-six were excluded from the evaluation for various
reasons. Four patients died before the first control evaluation at six months; a 24 year
old man committed suicide; a 70 year old woman died of cardiac insufficiency; a 76 year
old man died of gastrointestinal hemorrhage; and a 75 year old man died of a cerebral
hemorrhage. Seventeen patients did not attend for ultrasonography at 6 and
12 months; ten patients' practitioners were called and confirmed that these persons had
developed no biliary symptoms during the year following the end of the antibiotic
treatment. In two of these ten, a sonography of the gallbladder performed at three
months was normal. No details were obtained in seven patients. Two patients had
antibiotics for less than seven days and two received further treatment with amoxy-
cillin/clavulanate and/or ceftriaxone during the follow-up period. One patient was
randomized but should have been excluded because he had a cholecystectomy two
years before the study.
Demographic data from the 74 patients who could be evaluated are shown in Table I.
The mean age of the ceftriaxone group was slightly higher than amoxycillin/clavula-
nate, but this difference was not statistically significant. The distribution of infections
by site and organisms is summarized in Table II. Urinary tract (51 %), pulmonary tract
(16%) and ENT (9-5%) infections were the most frequent infectious sites treated. The
infective microorganisms were mainly Escherichia coli, which represented 50% of the
microbiologically documented infections.
Gallbladder lithiasis or precipitation was seen in five patients belonging to the
ceftriaxone group and in five patients in the amoxycillin/clavulanate group (see
Table L Demographic data—cvaluable patients
Patients' number
man
woman
Age (years)
median
average (±S.D.)
range
Treatment duration (days)
median
average (±s.D.)
range
Amoxycillin/
clavulanate
(4-6xl-2g/d)
34
11
23
42
44-2 (±19-4)
17-78
14
16.8 (±104)
7-59
Ceftriaxone
(2g/d)
40
20
20
52
51-4 (±18-8)
20-77
11
17-6 (±16-2)
7-87
P
009
009
Oil
028
082
S.D., Standard deviation.
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Tabk IL Distribution of infections by site and
organisms
Site
Urinary
Pulmonary
ENT
Sepsis
Others'
Organisms
E. coli
Klebsiella sp.
Proteus sp.
Streptococcus
Others*
> 1 organism
No organism
Amoxycillin/
clavulanate
15
6
5
4
4
16
1
0
3
1
3
10
Ceftriaxone
23
6
2
3
6
15
3
3
7
3
4
5
•Cerebral abcess: 2, endocarditis: 2, osteitis: 2,
fever of unknown origin: 2, enteritir 1, erysipelas: 1.
'Haemophihis infjueniar. 1, Staphylococcus aureur.
2, Proptonibacter spp.: 1.
Table III. Incidence of biliary stone (b.s.) or precipitation (b.p.)
74 evaluable patients
Amoxycillin/
clavulanate
n = 34
5 b.s.
Ceftriaxone
n-AO
5 b.s.
or b.p.
2 pre-
existing
b.s.
2 probably
preexisting
b.s.
1 new
b.s.
1 pre-
existing
b.s.
2 probably
preexisting
b.s.
2 new
b.p.
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Table HI). For one patient in the ceftriaxone group and two patients in the amoxycillin/
clavulanate group the sonography performed at days — 1 and 0 showed a calculus, so
that lithiasls preceded antibacterial treatment. For two patients in each group, the
lithiasis was probably preexisting, although the first control sonography was not
performed until two to six days after treatment began: for these four patients, neither
the size nor the number of calculi changed during the one year follow-up. In one
patient treated with amoxycillin/clavulanate, the gallbladder was not seen at the first
control; at six months, a biliary precipitation was observed, but this had been noted in
an ultrasonography performed two years before the study.
In one patient receiving ceftriaxone, three small calculi and a biliary precipitation
were seen one day after treatment started. The calculi were still present at further
evaluation but the biliary precipitation was not described any more. In another patient
who received ceftriaxone for IS days for an E. coli pyelonephritis, binary ultrasono-
graphy performed at the end of ceftriaxone treatment for a reason other than biliary
symptomatology, showed binary precipitation: while this patient did not return for the
six months follow-up, the biliary ultrasonography was normal at 12 months.
Gallbladder lithiasis developed during the follow-up in one patient treated with
amoxycillin/clavulanate for an enteritis in whom the sonography control at six months
was normal, but a calculus was seen in the fundus at 12 months.
Discussion
Unlike many cephalosporins, ceftriaxone is only partially eliminated by the kidneys:
the other elimination pathway is biliary and is responsible for the high therapeutic
potential of ceftriaxone in biliary tract infections. Studies (Hayton et al., 1986; Hayton
& Stoeckel, 1986) in patients in whom a T-drain was placed after cholecystectomy
showed that 10-20% of the ceftriaxone injected was eliminated by the bile; this was
similar to observations in volunteers in whom the ceftriaxone levels were measured in
duodenal aspirate. Tolerance studies in dogs and monkeys (Teehnann et al., 1982)
given high doses of ceftriaxone for prolonged periods of time have shown that
precipitates could appear in the gallbladder of some animals- these precipitates
contained 30-50% taurocholic acid, 10% lecithin and 30-40% calcium salts of
ceftriaxone. These events were observed in dogs and monkeys given high doses of
ceftriaxone (100 and 400 mg/kg/day), when ceftriaxone was administrated for 4 and
26 weeks respectively.
Like ceftriaxone, cefoperazone, another third generation cephalosporin, is partly
eliminated by the bile, biliary elimination having been estimated to be about 15%
(Kemmerich et al., 1983). To our knowledge, there are no data about an association
between cefoperazone and the formation of gallbladder precipitations. Schaad, Tschap-
peler & Lentze (1986) & Schaad & Tschaappeler (1987) have described the transient
formation of gallstones in the gallbladder of two children given ceftriaxone therapy, in
whom echogenic material was seen during ceftriaxone treatment and disappeared after
stopping ceftriaxone. More recently, the same authors performed a prospective study
(Schaad, Wedgwood-Krucko & Tschappeler, 1988) in which young patients receiving
ceftriaxone therapy once-a-day (lOOmg/kg) had serial sonographic evaluations. Tran-
sient precipitations (hyperechogenic material with shadow) were found in 16 of
37 patients within 4-22 days after ceftriaxone treatment began. In this small patient
population, it seemed that biliary precipitations were more common when ceftriaxone
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was administered by short bolus than with 30 min infusion administration. Normalized
sonograms taken within 2-63 days after the end of ceftriaxone treatment were obtained
in all these patients. A control group with 22 patients treated with cefuroxime did not
show any ultrasonographic abnormality.
Another prospective trial (Heim-Duthoy et al., 1988) in 24 patients receiving
ceftriaxone for 14 days oncc-a-day (30 min infusion) demonstrated biliary precipitation
on day 14 in six of 24 patients; these gallbladder abnormalities resolved spontaneously
two to three weeks after the end of ceftriaxone therapy. In the control group receiving a
placebo, none of nine patients developed a biliary precipitation.
Situations responsible for gallbladder stasis such as dehydration (Callahan et al.,
1982) fasting (Bolondi et al., 1985) or total parenteral nutrition (Roslyn et al., 1983;
Messing et al., 1983) are known to further biliary precipitations. Of course, one cannot
exclude the presence of these factors in Schaad's and Heim-Duthoy's studies. However,
both studies had a control group that did not show any biliary precipitations, so that
these studies provide convincing evidence that ceftriaxone treatment could cause
transitory biliary precipitations.
The purpose of the present study was not to detect precipitation or stone formation
during ceftriaxone treatment (neither phenomena were known at the beginning of the
study), but to investigate whether ceftriaxone could be responsible for the formation of
gallbladder lithiasis in humans within a one year follow-up. No gallbladder lithiasis
developed during the follow-up. Only in two patients treated with ceftriaxone were
transient biliary precipitations found: these two patients were asymptomatic, with liver
enzyme studies remaining normal. Biliary precipitation was seen in the first patient
when he had fasted for ten days before the baseline sonography and he had received
only one dose of ceftriaxone. In the second patient, biliary precipitation was discovered
after 14 days of ceftriaxone treatment when she had not fasted. Other factors such as
dehydration or total parenteral nutrition were absent in these two patients. The small
group sizes and the low incidence of lithiasis in the control group mean that the results
of the study cannot exclude a small difference in the incidence of lithiasis between the
treatment groups. Indeed, given the relatively low number of patients enrolled, the
study had a power of 55% to detect a five-fold increase of biliary stone after ceftriaxone
treatment and of 95% to detect a ten-fold increase.
In conclusion, despite the elimination of ceftriaxone through the bile and the
description of ceftriaxone salt precipitates in experimental animals after prolonged
administration, ceftriaxone treatment did not lead to gallstone formation more often
than an antibiotic not eliminated through the bile in the present study. However, our
study design did not allow conclusions about ceftriaxone and the formation of biliary
precipitation during treatment.
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